- Home
- PULM vs AIXI Comparison
PULM vs AIXI Comparison
Compare PULM & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- AIXI
- Stock Information
- Founded
- PULM 2003
- AIXI 2001
- Country
- PULM United States
- AIXI China
- Employees
- PULM N/A
- AIXI N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- AIXI Computer Software: Prepackaged Software
- Sector
- PULM Health Care
- AIXI Technology
- Exchange
- PULM Nasdaq
- AIXI Nasdaq
- Market Cap
- PULM 33.2M
- AIXI 31.2M
- IPO Year
- PULM N/A
- AIXI 2023
- Fundamental
- Price
- PULM $6.50
- AIXI $2.32
- Analyst Decision
- PULM
- AIXI
- Analyst Count
- PULM 0
- AIXI 0
- Target Price
- PULM N/A
- AIXI N/A
- AVG Volume (30 Days)
- PULM 60.7K
- AIXI 130.2K
- Earning Date
- PULM 08-12-2025
- AIXI 05-15-2025
- Dividend Yield
- PULM N/A
- AIXI N/A
- EPS Growth
- PULM N/A
- AIXI N/A
- EPS
- PULM N/A
- AIXI N/A
- Revenue
- PULM $1,921,000.00
- AIXI $70,314,315.00
- Revenue This Year
- PULM N/A
- AIXI $26.84
- Revenue Next Year
- PULM $134.88
- AIXI N/A
- P/E Ratio
- PULM N/A
- AIXI N/A
- Revenue Growth
- PULM N/A
- AIXI 18.84
- 52 Week Low
- PULM $1.78
- AIXI $2.06
- 52 Week High
- PULM $10.40
- AIXI $8.31
- Technical
- Relative Strength Index (RSI)
- PULM 39.79
- AIXI 43.02
- Support Level
- PULM $6.26
- AIXI $2.27
- Resistance Level
- PULM $6.96
- AIXI $3.10
- Average True Range (ATR)
- PULM 0.87
- AIXI 0.28
- MACD
- PULM -0.12
- AIXI -0.00
- Stochastic Oscillator
- PULM 40.16
- AIXI 28.82
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.